Tarsus Pharmaceuticals (TARS) Non-Current Assets (2019 - 2026)

Tarsus Pharmaceuticals' Non-Current Assets history runs 8 years deep, the most recent figure standing at $43.9 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 119.78% year-over-year to $43.9 million; the TTM figure through Mar 2026 stood at $136.7 million (up 85.48% YoY), while the FY2025 annual figure was $39.4 million, up 94.1% from the prior year.
• Non-Current Assets for Q1 2026 stood at $43.9 million, up from $39.4 million in the prior quarter.
• The five-year high for Non-Current Assets was $43.9 million in Q1 2026, with the low at $2.4 million in Q3 2022.
• The 5-year median for Non-Current Assets is $9.4 million (2023), against an average of $15.0 million.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets retreated 28.19% in 2022, then jumped 279.35% in 2023.
• Tarsus Pharmaceuticals' Non-Current Assets stood at $2.5 million in 2022, then soared by 276.21% to $9.4 million in 2023, then jumped by 116.73% to $20.3 million in 2024, then soared by 94.1% to $39.4 million in 2025, then increased by 11.5% to $43.9 million in 2026.
• Business Quant data shows TARS's Non-Current Assets at $43.9 million in Q1 2026, $39.4 million in Q4 2025, and $32.9 million in Q3 2025.